TITLE
Infantile-onset Pompe response to recombinant human lysosomal acid alpha-glucosidase (rhGAA) treatment: quadriceps

SUMMARY
Analysis of quadriceps biopsies from infantile-onset Pompe disease patients treated with recombinant human lysosomal acid alpha-glucosidase (rhGAA, Myozyme) for up to 52 weeks. Results provide insight into molecular mechanisms underlying the response to therapy (positive vs. poor clinical outcome).

ORGANISM
Homo sapiens

PLATFORM
GPL570 : [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array

CITATIONS
Palermo AT, Palmer RE, So KS, Oba-Shinjo SM et al. Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients. Mol Genet Metab 2012 Jul;106(3):287-300. PMID:Â  22658377

